IPO registrations (S-1, F-1) · Registrants
Apellis Pharmaceuticals, Inc.
- SEC CIK
- 1492422 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2015-10-13, last 2018-04-16; 3 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2017-11-09; declared effective 2017-11-08; withdrawal requested 2016-02-08
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 100 FIFTH AVENUE, Waltham, MA 02451
- EIN
- 27-1537290
- EDGAR entity type
- operating
- Insiders and CEO pay
- Apellis Pharmaceuticals, Inc. on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2017-10-30)
- Final price
- $14.00 per share, within the range (424B4 filed 2017-11-09, an initial public offering)
- Shares sold
- 10,714,000
- Gross proceeds
- $149,996,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol APLS
- Lead underwriters
- Citigroup; J.P. Morgan (4,285,600 shares); Evercore (2,142,800 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Apellis Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: Apellis Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: APELLIS PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: APELLIS PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: APELLIS PHARMACEUTICALS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: APELLIS PHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- Form D issuer: Apellis Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- SEC filer: Apellis Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- Person page: Craig A Wheeler Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Stephanie Monaghan O'Brien Jd Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 14
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-10-13 | S-1 | S-1 (registration) | Apellis Pharmaceuticals, Inc. | 0001193125-15-342824 ↗ |
| 2015-11-02 | S-1/A | S-1/A (amendment) | Apellis Pharmaceuticals, Inc. | 0001193125-15-362509 ↗ |
| 2016-02-08 | RW | RW (withdrawal request) | Apellis Pharmaceuticals, Inc. | 0001193125-16-453827 ↗ |
| 2017-10-13 | S-1 | S-1 (registration) | Apellis Pharmaceuticals, Inc. | 0001193125-17-309813 ↗ |
| 2017-10-20 | S-1/A | S-1/A (amendment) | Apellis Pharmaceuticals, Inc. | 0001193125-17-315537 ↗ |
| 2017-10-27 | S-1/A | S-1/A (amendment) | Apellis Pharmaceuticals, Inc. | 0001193125-17-323102 ↗ |
| 2017-10-30 | S-1/A | S-1/A (amendment) | Apellis Pharmaceuticals, Inc. | 0001193125-17-324222 ↗ |
| 2017-11-08 | EFFECT | EFFECT (declared effective) | Apellis Pharmaceuticals, Inc. | 9999999995-17-002925 ↗ |
| 2017-11-09 | 424B4 | 424B4 (final prospectus) | Apellis Pharmaceuticals, Inc. | 0001193125-17-338588 ↗ |
| 2018-04-16 | S-1 | S-1 (registration) | Apellis Pharmaceuticals, Inc. | 0001193125-18-118655 ↗ |
| 2018-04-18 | S-1MEF | S-1MEF (added securities) | Apellis Pharmaceuticals, Inc. | 0001193125-18-121516 ↗ |
| 2018-04-18 | EFFECT | EFFECT (declared effective) | Apellis Pharmaceuticals, Inc. | 9999999995-18-000858 ↗ |
| 2018-04-19 | 424B4 | 424B4 (final prospectus) | Apellis Pharmaceuticals, Inc. | 0001193125-18-122634 ↗ |
| 2019-11-18 | EFFECT | EFFECT (declared effective) | Apellis Pharmaceuticals, Inc. | 9999999995-19-002593 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-10-30 | S-1/A | registration statement | $13.00–$15.00 | 10,714,000 | - | Nasdaq APLS | 3 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 3 | document ↗ | |
| 2017-11-09 | 424B4 | final prospectus | $14.00 | 10,714,000 | $149,996,000 | Nasdaq APLS | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| AJU IB Investment Co., Ltd. | TenPercentOwner | 2 | 2017 | ||
| Axon Steven | Officer | Chief Business Officer | 3 | 2017–2018 | |
| Chan Gerald | Director | 10 | 2017–2026 | ||
| Chen Bihua | Director,TenPercentOwner | 2 | 2017 | ||
| Cormorant Asset Management, LLC | TenPercentOwner | 2 | 2017 | ||
| Cormorant Global Healthcare Master Fund, LP | TenPercentOwner | 2 | 2017 | ||
| CORMORANT PRIVATE HEALTHCARE FUND I, LP | TenPercentOwner | 1 | 2017 | ||
| Deschatelets Pascal | Officer | Chief Operating Officer; Chief Scientific Officer | 65 | 2017–2026 | |
| Dunlop A. Sinclair | Director | 47 | 2017–2026 | ||
| Francois Cedric | Director,Officer; Director,Officer,TenPercentOwner; Officer | Chief Executive Officer | 73 | 2017–2026 | |
| GELLERT MICHAEL E | TenPercentOwner | 2 | 2017 | ||
| Grossi Federico | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER; See Remarks | 62 | 2017–2023 | |
| Hillhouse Capital Management, Ltd. | TenPercentOwner | 2 | 2017 | ||
| Machiels Alec | Director | 59 | 2017–2026 | ||
| Morningside Venture Investments Ltd | TenPercentOwner | 7 | 2017–2021 | ||
| O'Brien Stephanie Monaghan | Director | 11 | 2017–2026 | person page Fuzzy | |
| Perry Nicole D | Officer | Vice President - Accounting; Vice President - Finance | 16 | 2017–2021 | |
| Potentia Holdings, LLC | TenPercentOwner | 1 | 2017 | ||
| Sullivan Timothy Eugene | Officer | Chief Financial Officer | 42 | 2017–2026 | |
| venBio Global Strategic Fund II L.P. | TenPercentOwner | 2 | 2017 | ||
| Watson David O. | Officer | General Counsel | 61 | 2017–2026 | |
| Cormorant Global Healthcare GP, LLC | TenPercentOwner | 1 | 2017 | ||
| SCHEIBLER LUKAS | Officer | CHIEF INNOVATION OFFICER; Chief Research Officer; See Remarks | 27 | 2018–2023 | |
| Lackner Thomas A. | Officer | See Remarks | 2 | 2019–2020 | |
| Sadr Ahmad | Officer | See Remarks | 2 | 2019–2020 | |
| Townsend Adam J. | Officer | Chief Commercial Officer; See Remarks | 35 | 2019–2025 | |
| Celona Lucia | Officer | See Remarks | 2 | 2019–2020 | |
| FONTEYNE PAUL R. | Director | 9 | 2020–2026 | ||
| Brown Victoria L. | Officer | Program Team Lead | 14 | 2020–2023 | |
| Lewis Karen | Officer | Chief People Officer | 22 | 2020–2025 | |
| Eisele Jeffrey | Officer | Chief Development Officer; Exec VP, Program Team Lead; See Remarks | 25 | 2020–2025 | |
| Nicholson Nur | Officer | Chief Technical Officer | 23 | 2020–2026 | |
| None | Director | 1 | 2021 | ||
| None | Officer | CHIEF MEDICAL OFFICER | 1 | 2021 | |
| DeLong Mark Jeffrey | Officer | Chief Business & Strat Officer; Senior Vice President | 43 | 2021–2026 | |
| Chopas James George | Officer | See Remarks; VP/Chief Accounting Officer | 31 | 2021–2026 | |
| Baumal Caroline | Officer | Chief Medical Officer | 13 | 2023–2026 | |
| Walbert Keli | Director | 4 | 2025–2026 | ||
| WHEELER CRAIG A | Director | 4 | 2025–2026 | person page Fuzzy | |
| Boucher Kelley | Officer | Chief People Officer | 6 | 2025–2026 | |
| MELTZER LESLIE | Officer | Chief Research and Development | 4 | 2025–2026 | |
| Dolsten Mikael | Director | 3 | 2026 | ||
| BIOGEN INC. | Other | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2017-08-17 | Apellis Pharmaceuticals, Inc. | Pharmaceuticals | $60,099,974 | $20,033,322 | 16 | 1 |
| 2016-02-08 | Apellis Pharmaceuticals, Inc. | Pharmaceuticals | $47,135,951 | $47,135,951 | 7 | 1 |
| 2016-01-06 | Apellis Pharmaceuticals, Inc. | Pharmaceuticals | $32,135,952 | $32,135,952 | 6 | 1 |
| 2014-12-17 | Apellis Pharmaceuticals, Inc. | Biotechnology | $17,732,150 | $17,732,150 | 1 | 2 |
| 2014-08-27 | Apellis Pharmaceuticals, Inc. | Pharmaceuticals | $24,000,000 | $17,842,487 | 25 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Apellis Pharmaceuticals, Inc. | MA | State business registries | name and state |
| Business registration | Apellis Pharmaceuticals, Inc. | MA | State business registries | name and state |
| Business registration | APELLIS PHARMACEUTICALS, INC. | MA | State business registries | name and state |
| Business registration | APELLIS PHARMACEUTICALS, INC. | MA | State business registries | name and state |
| Business registration | APELLIS PHARMACEUTICALS, INC. | MA | State business registries | name and state |
| Form D issuer | Apellis Pharmaceuticals, Inc. | KY | Form D private offerings | CIK (EXACT) |
| IPO registrant | STORAGENETWORKS INC | MA | IPO registrations (S-1, F-1) | same street address and ZIP code, 100 FIFTH AVE 02451 (FUZZY: a shared address, not proof of a shared organization) |
| Paying company | Apellis Pharmaceuticals, Inc. | MA | Open Payments (drug and device company payments) | name and state |
| Patent assignee | Apellis Pharmaceuticals, Inc. | MA | Patents (USPTO) | name and state |
| SEC filer | Apellis Pharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Apellis Pharmaceuticals, Inc. | MA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | APELLIS PHARMACEUTICALS, INC. | EIN (EXACT) | ||
| Person page | Craig A Wheeler | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Stephanie Monaghan O'Brien Jd | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MA first:
- ERGO SCIENCE CORP MA
- MILLENNIUM PHARMACEUTICALS INC MA
- ESSENTIAL THERAPEUTICS INC MA
- ARQULE INC MA
- ASCENT PEDIATRICS INC MA
- EPIX Pharmaceuticals, Inc. MA
- PRAECIS PHARMACEUTICALS INC MA
- PARATEK PHARMACEUTICALS INC MA
- PREDIX PHARMACEUTICALS HOLDINGS INC MA
- CervoMed Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health